Ran Ni1, Tal Peleg, Peter L Gross. 1. Thrombosis and Atherosclerosis Research Institute, 237 Barton St East, Hamilton, Ontario, L8L 2X2 Canada.
Abstract
OBJECTIVE: Statins decrease mortality in patients with vascular disorders, and evidence for the pleiotropic effects of statins is accumulating. Statins enhance endothelial NO synthase (eNOS) expression, thereby attenuating platelet activation and thrombus formation. Our goal was to determine whether statins have eNOS-independent effects on platelet activation. METHODS AND RESULTS: Wild-type and eNOS-deficient mice were given a 14-day course of oral atorvastatin, and platelet activation was evaluated in vitro and in vivo. Whereas in wild-type mice atorvastatin inhibited platelet activation in vitro in response to numerous agonists, in eNOS-deficient mice, atorvastatin inhibited only thrombin-induced and protease-activated receptor 4 agonist peptide-induced platelet activation. Consistent with an eNOS-independent effect, atorvastatin inhibited platelet activation in vivo in both wild-type and eNOS-deficient mice. CONCLUSIONS: Atorvastatin inhibits platelet activation via eNOS-dependent and eNOS-independent mechanisms with the latter restricted to protease-activated receptor 4-induced activation downstream to the receptor.
OBJECTIVE: Statins decrease mortality in patients with vascular disorders, and evidence for the pleiotropic effects of statins is accumulating. Statins enhance endothelial NO synthase (eNOS) expression, thereby attenuating platelet activation and thrombus formation. Our goal was to determine whether statins have eNOS-independent effects on platelet activation. METHODS AND RESULTS: Wild-type and eNOS-deficient mice were given a 14-day course of oral atorvastatin, and platelet activation was evaluated in vitro and in vivo. Whereas in wild-type miceatorvastatin inhibited platelet activation in vitro in response to numerous agonists, in eNOS-deficient mice, atorvastatin inhibited only thrombin-induced and protease-activated receptor 4 agonist peptide-induced platelet activation. Consistent with an eNOS-independent effect, atorvastatin inhibited platelet activation in vivo in both wild-type and eNOS-deficient mice. CONCLUSIONS:Atorvastatin inhibits platelet activation via eNOS-dependent and eNOS-independent mechanisms with the latter restricted to protease-activated receptor 4-induced activation downstream to the receptor.
Authors: Bibian M E Tullemans; Sanne L N Brouns; Frauke Swieringa; Siamack Sabrkhany; Franchette W P J van den Berkmortel; Natascha A J B Peters; Peter de Bruijn; Stijn L W Koolen; Johan W M Heemskerk; Maureen J B Aarts; Marijke J E Kuijpers Journal: BMC Cancer Date: 2022-06-13 Impact factor: 4.638
Authors: Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim Journal: J Thromb Haemost Date: 2020-09 Impact factor: 5.824
Authors: Chase W Kessinger; Jin Won Kim; Peter K Henke; Brian Thompson; Jason R McCarthy; Tetsuya Hara; Martin Sillesen; Ronan J P Margey; Peter Libby; Ralph Weissleder; Charles P Lin; Farouc A Jaffer Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240
Authors: Antonio Nenna; Francesco Nappi; Mario Lusini; Umberto Maria Satriano; Davide Schilirò; Cristiano Spadaccio; Massimo Chello Journal: Biomed Res Int Date: 2021-01-23 Impact factor: 3.411